New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5749+0.0075 (+1.32%)
At close: 04:00PM EDT
0.5751 +0.00 (+0.03%)
After hours: 07:49PM EDT

Spruce Biosciences, Inc.

611 Gateway Boulevard
Suite 740
South San Francisco, CA 94080
United States
415 655 4168

Full-time employees22

Key executives

NameTitlePayExercisedYear born
Mr. Michael G. GreyExecutive Chairman70kN/A1953
Dr. Javier Szwarcberg M.D., M.P.H.CEO & Director951.85kN/A1970
Mr. Samir M. Gharib CPA, M.B.A.President & CFO683.63kN/A1982
Dr. Ralph William Charlton III, M.D.Chief Medical Officer647.4kN/A1970
Ms. P. J. RamtinSenior Vice President of Business OperationsN/AN/AN/A
Ms. Heidi Petersen M.P.H.Senior Vice President of Regulatory & QualityN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Corporate governance

Spruce Biosciences, Inc.’s ISS governance QualityScore as of 1 July 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.